Vanta Diagnostics

What Vanta Diagnostics does

Vanta Diagnostics is a PE-backed molecular diagnostics laboratory platform that provides rapid PCR-based pathogen detection and antibiotic resistance gene identification to healthcare providers across the United States. The company offers a portfolio of ten trademarked, disease-specific test panels (Wound-ID™, Urine-ID™, Derm-ID™, Gastro-ID™, Joint-ID™, Nail-Fungal-ID™, Respira-ID™, STI-ID™, Surgical-ID™, and Vaginal-ID™) plus a comprehensive resistance gene panel covering up to 49 resistance genes across 13 antibiotic classes, COVID-19 RT-PCR testing, pharmacogenetic testing, and anatomical pathology services through wholly-owned subsidiary KorPath. Testing is performed on Applied Biosystems QuantStudio 5 instrumentation with TaqMan assays, and results are delivered within 24 hours of specimen arrival, accompanied by PharmD-guided treatment recommendations that incorporate published susceptibility patterns, medication costs, antibiotic spectrum, and FDA guidance.

Vanta generates revenue primarily on a transaction-fee basis through laboratory testing services reimbursed by Medicare, Medicaid, Tricare, and commercial insurance, with a $100 cash-pay price for uninsured COVID-19 patients and a Patient Financial Hardship Program. Go-to-market is executed through a national sales organization of 100+ professionals, direct account enrollment, and bi-directional EMR/EHR integration with more than 200 systems including Epic, Cerner, athenahealth, eClinicalWorks, and NextGen, alongside provider and sales portals for ordering and account management. The company also operates a Corporate Account Assist Program targeting assisted living and memory care facilities. Lab operations are CLIA-certified and CAP-accredited in South Carolina, Pennsylvania, and Florida, supporting service across 45 states.

The platform was formed in 2025 when Author Capital Partners, through its Author Equity Capital I, LP fund, acquired key diagnostics assets and combined them with the legacy Vikor Scientific operation, subsequently rebranding the entity as Vanta Diagnostics in February 2026 under new leadership led by CEO Chris Howlett. Author Capital has indicated that additional acquisitions are planned, framing Vanta as a roll-up vehicle targeting the estimated $100 billion U.S. lab testing and diagnostics market.

Name

Vanta Diagnostics

Legal name

Vanta Diagnostics, LLC

Website

https://vantadiagnostics.com

Company type

Private

Founded year

2025

Operating status

Operating

Headcount range

101–250 employees

Short description

Vanta Diagnostics is a PE-backed molecular diagnostics platform providing rapid PCR-based pathogen detection and resistance gene testing to U.S. healthcare providers across 45 states, with disease-specific panels and PharmD-guided treatment recommendations.

Ownership category

akta.pro rank

Product category

Molecular Diagnostic Laboratory Services

NAICS

Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151)

SIC

Services-Medical Laboratories (8071)

akta.pro primary industry

Molecular & Genetic Testing (PCR/NGS/qPCR) (HLAGADAF)

akta.pro secondary industries

Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays) (HLAAALAL), Infectious Disease POCT (Respiratory, STI, HIV, Sepsis) (HLAHAOAA)

Keywords

• Molecular diagnostic testing
• PCR pathogen detection
• Antibiotic resistance testing
• Infectious disease diagnostics
• Anatomical pathology services

Headquarters

HQ city

Charleston

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure, Supply Chain

Revenue model

1. Molecular Diagnostic Testing Services: Laboratory testing services for molecular diagnostics including pathogen detection and resistance gene identification. Revenue generated from billable laboratory tests covered by Medicare, Medicaid, Tricare, and commercial insurance plans. Also offers COVID-19 testing at $100 cash price for uninsured patients.
2. Pharmacy Consult Services: Clinical consultation services provided by PharmD professionals to assist providers in choosing appropriate treatment plans based on diagnostic results

Pricing tiers

Go-to-market motion3 records

Distribution channels5 records

Marketing channels6 records

Core offering

Vanta Diagnostics provides molecular diagnostic testing using PCR-based technology for rapid pathogen detection and antibiotic resistance gene identification. The company operates a portfolio of disease-specific test panels covering wound, urine, dermatological, gastrointestinal, joint, nail fungal, respiratory, STI, surgical site, and vaginal infections, with results typically delivered within 24 hours of specimen arrival. In addition to molecular diagnostics, the company offers anatomical pathology services through its wholly-owned subsidiary KorPath, complemented by PharmD clinical guidance for treatment selection.

Product overview

Vanta Diagnostics operates as a molecular diagnostics company offering a portfolio of targeted PCR-based pathogen detection panels across multiple body systems. The core product line includes disease-specific panels (Wound-ID™, Urine-ID™, Derm-ID™, Gastro-ID™, Joint-ID™, Nail-Fungal-ID™, Respira-ID™, STI-ID™, Surgical-ID™, Vaginal-ID™) that detect pathogens and antibiotic resistance genes within 24 hours of specimen arrival. Additional offerings include Pharmacogenetics testing and Covid-19 RT-PCR testing. The company also provides Antibiotic Resistance Testing as a comprehensive panel covering 49 resistance genes in 13 antibiotic classes. Anatomical pathology solutions are delivered through a wholly owned subsidiary. All molecular diagnostic results are accompanied by PharmD guidance that considers published sensitivity patterns, medication costs, and FDA guidance to support targeted treatment decisions.

Differentiator

Problem solved

Functional benefit

Brands

• Wound-ID™: Rapid molecular wound pathogen detection and resistance gene identification
• Urine-ID™
• Derm-ID™
• Gastro-ID™
• Joint-ID™
• Nail-Fungal-ID™
• Respira-ID™
• STI-ID™
• Surgical-ID™
• Vaginal-ID™
• Pharmacogenetics

Products and services

• Wound-ID™

Quantifiable outcome

• Results within 24 hours from specimen arrival at the lab
• +4 more outcomes

Segments7 records

Ideal customer profiles5 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration41 records

Feature4 records

Partnerships

Four partnerships are on record, tiered core and secondary.

• Chris HowlettcoreOthers · 1 January 2025Industry veteran Chris Howlett partnered with Author Capital Partners to lead the acquisition creating Vanta Diagnostics. Howlett brings over three decades of experience in the diagnostics laboratory industry, having previously co-founded Market Street Healthcare Partners and served as Chairman and CEO of Genelex (acquired by Invitae).
• Advanced Therapeutic Assist (ATA)secondaryStrategic or Co-development PartnerPartnership delivers comprehensive infectious disease management combining rapid molecular diagnostics with expert-guided pharmacotherapy. ATA's proprietary model integrates laboratory services with targeted therapeutic management to support precise treatment decisions. The partnership combines PCR technology with resistance gene detection to help providers select appropriate therapy faster while supporting antibiotic stewardship and improving patient outcomes.
• South Carolina Research Authority (SCRA)secondaryStrategic or Co-development PartnerSCRA is a public, nonprofit organization founded in 1983 dedicated to fueling innovation across South Carolina. The organization supports research-driven companies through funding, facilities, and commercialization resources. Vanta Diagnostics values SCRA's role in advancing science-driven solutions and supporting long-term economic growth in South Carolina's technology ecosystem.
• SCBIOsecondaryStrategic or Co-development PartnerSCBIO is South Carolina's life sciences industry organization focused on growing and advancing innovation across biotechnology, healthcare, and medical technology. As an investor-driven public-private partnership, SCBIO represents companies, institutions, and leaders driving research, development, and commercialization. Vanta Diagnostics aligns with SCBIO's mission to foster collaboration and accelerate life science innovation.

Scale indicators4 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• Inform Diagnostics: Specialty anatomic and molecular pathology lab serving gastroenterology, dermatology, and urology practices. Closely comparable to Vanta's specialty-vertical strategy and resistance/molecular menu in those segments.
• PathGroup: Private, physician-led pathology and molecular diagnostics provider with hospital and specialty-physician focus. Comparable to Vanta in offering molecular + anatomic pathology with rapid turnaround to community providers.
• Eurofins Viracor: Specialty molecular diagnostics lab focused on infectious disease, immunology, and transplant testing. Closely comparable to Vanta in PCR-based infectious disease panels, resistance gene testing, and specialty-provider distribution.

Others

• Copan Diagnostics: Manufacturer of pre-analytic specimen collection and transport systems used widely in molecular infectious disease testing. Adjacent peer serving the same customer workflows and often co-marketed with PCR-based labs like Vanta.

Emerging players

• Accelerate Diagnostics: Specialty molecular diagnostics company focused on rapid antibiotic susceptibility and resistance identification. Overlaps with Vanta's resistance gene and antimicrobial stewardship value proposition.
• T2 Biosystems: Molecular diagnostics company developing rapid sepsis and resistance detection panels. Comparable to Vanta in the molecular infectious disease space and the focus on resistance gene identification, but with platform-based rather than lab-service delivery.
• Meridian Bioscience (Revvity): Diagnostics company with molecular infectious disease test kits and reagents including H. pylori, C. difficile, and respiratory panels. Comparable to Vanta in molecular GI and respiratory pathogen detection, but as a kit/reagent provider rather than lab service.

Broad incumbents

• Quest Diagnostics: The largest US clinical laboratory, offering a broad molecular infectious disease menu and nationwide logistics. Directly comparable to Vanta as a national PCR-based testing provider serving physicians, though Quest's portfolio extends well beyond infectious disease.
• Sonic Healthcare (Aurora Diagnostics): Global lab operator whose Aurora Diagnostics subsidiary focuses on anatomic and molecular pathology in the US. Comparable to Vanta's KorPath and broader molecular menu, with national reach and a similar specialty-physician go-to-market.
• Laboratory Corporation of America (Labcorp): Major US clinical lab with extensive molecular diagnostics and anatomic pathology offerings. Closely comparable to Vanta in lab services, EMR integrations, and payor relationships, but operates at far greater scale across all specialties.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/vanta-diagnostics

Compliance7 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vanta Diagnostics